Safety and Effectiveness of Blood-Brain Barrier Disruption (BBBD) in Subjects With Suspected Infiltrating Glioma

Glioma Clinical Trial

— BBBD  

Official title:

A Pivotal Study to Evaluate the Safety and Effectiveness of Exablate Model 4000 Using Microbubble Resonators to Temporarily Mediate Blood-Brain Barrier Disruption (BBBD) in Subjects With Suspected Infiltrating Glioma

Clinical Trial Details — Status: Suspended

Administrative data

• NCT number: NCT04667715
• Other study ID #: BT011
• Status: Suspended
• Phase: N/A
• Start date: December 2024
• Est. completion date: June 2026

Study information

• Verified date: March 2024
• Source: InSightec
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and effectiveness of using the Exablate Type 2 system using microbubble resonators (Exablate Test Arm) to disrupt the Blood-Brain Barrier for the purpose of temporarily transforming, and thereby 'marking', regions of infiltrating gliomas prior to planned surgical resection, for the purpose of improving tumor visualization during the surgery to achieve a greater proportion of subjects who receive a Gross Total Resection (GTR) per plan compared to those not undergoing a BBBD procedure prior to resection (Control Arm).

Description:

After being informed about the study and potential risks, all patients giving written informed consent will undergo screening to determine eligibility for study entry. Patients who meet the eligibility requirements will be randomized in a 2:1 ratio to Exablate Test Arm and to Control Arm, respectively. The following assessments will occur:

1. Pre-surgical planning and Post-surgical visit MRI exams with and without contrast will be collected for evaluation by the study core lab; Any return to surgery for additional resection will be captured

2. All subjects will be seen at ~Week 2, and ~4-Weeks post resection for physical and neurological exams and to assess for complications or adverse events. These visits should coincide with standard (Neuro-oncology) care following resection.

3. Long-term outcomes will be collected during standard of care Neuro-oncology care follow-up visits for up to 2 years post resection; standard of care MRIs and RANO assessments will be collected.

Recruitment information / eligibility

• Status: Suspended
• Enrollment: 120
• Est. completion date: June 2026
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Male or Female between 21-85 years of age who are able and willing to give informed consent

2. Subjects with suspected Grade II, III or IV infiltrating glioma (IG) on pre-operative brain imaging scans who have a non-enhancing component and are planned for surgical resection.

3. Karnofsky Performance Score 70-100

4. Able to communicate sensations during the Exablate BBBD procedure

Exclusion Criteria:

1. Tumor originating from the deep midline, thalamus, midbrain, cerebellum or brainstem.

2. Multifocal tumors

3. MRI or clinical findings of:

1. Active or chronic infection(s) or inflammatory processes

2. Acute or chronic hemorrhages, specifically any lobar microbleeds, and no siderosis, amyloid angiopathy, or macro-hemorrhages

3. Intracranial thrombosis, vascular malformation, cerebral aneurysm or vasculitis

4. More than 30% of the skull area traversed by the sonication pathway is covered by scars, scalp disorders (e.g., eczema), or atrophy of the scalp

5. MR non-compatible metallic implants in the skull or the brain or the presence of unknown MR unsafe devices

6. Significant cardiac disease or unstable hemodynamic status

1. Documented myocardial infarction within six months of enrollment

2. Unstable angina on medication

3. Unstable or worsening congestive heart failure

4. Left ventricular ejection fraction below the lower limit of normal

5. History of a hemodynamically unstable cardiac arrhythmia

6. Cardiac pacemaker

7. Patient has right-to-left, bidirectional, or transient right-to-left cardiac shunts

8. Subjects with relative contraindications to perflutren including subjects with a family or personal history of QT prolongation or taking concomitant medications known to cause QTc prolongation,

9. Perflutren sensitivity or allergy ii. QT prolongation observed on screening ECG (QTc > 450 for men and >470 for women)

7. Uncontrolled hypertension (systolic > 180 and diastolic BP > 120 on medication)

8. Unable to discontinue use of anti-coagulant/antiplatelet therapy as per local standard.

9. History of a liver disease, bleeding disorder, coagulopathy or a history of spontaneous hemorrhage or evidence of increased risk of bleeding

10. Abnormal coagulation profile (Platelets < 80,000), PT (>14) or PTT (>36), and INR > 1.3.

11. Large lacunar lesions that cannot be navigated around

12. Known cerebral or systemic vasculopathy

13. Significant depression and at potential risk of suicide

14. Known sensitivity/allergy to gadolinium, or other intravascular contrast agents

15. Active seizures despite medication treatment (defined as >1 seizure per week) which could be worsened by disruption of the blood brain barrier

16. History of anaphylactic shock

17. Active drug or alcohol disorder which have a higher risk for seizures, infection and/or poor executive functioning

18. Positive HIV status, which can lead to increased entry of HIV into the brain parenchyma leading to HIV encephalitis

19. Potential blood-borne infections which can lead to increased entry to brain parenchyma leading to meningitis or brain abscess

20. Any contraindications to MRI scanning,

21. Impaired renal function with estimated glomerular filtration rate <30 mL/min/1.73m2

22. Severe Respiratory Illness

23. Currently in a clinical trial involving an investigational product or non-approved use of a drug or device

24. Pregnancy or Lactation

Related Conditions & MeSH terms

• Glioma

Intervention

Device:
• Exablate BBBD
Blood brain barrier disruption using ExAblate Type 2 device using microbubble resonators

Locations

Country	Name	City	State
United States	University of Maryland	Baltimore	Maryland
United States	The University of Texas MD Anderson Cancer Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
InSightec

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Evaluation of circulating tumor biomarkers	Collection of blood for evaluation of circulating tumor biomarkers (e.g. circulating tumor DNA [ctDNA])	pre- and post-BBBD procedure
Primary	Overall safety of the Exablate BBBD procedure itself as measured through the collection of adverse events	Safety of the Exablate BBBD procedure will be evaluated by patient examination and post-procedure MRI exams assessing changes in the treated region. Adverse events will be reported by the Investigator and monitored in both treatment arms.	Approximately 2 months
Primary	Effectiveness of BBBD as determined by the proportion of subjects in whom a GTR is acheived	The proportion of subjects in whom a gross total resection (actual versus planned) is achieved as measured on post-operative imaging compared to pre-resection imaging	MRI 72 hours post resection
Secondary	Confirmation of accuracy of Exablate BBBD targeting	Confirmation that new BBBD by contrast enhancement in a previously non-enhancing area overlies the intended target for BBBD. (ExAblate arm only)	MRI immediately after the ExAblate procedure
Secondary	Return Rate for Second Surgery for Completion of Resection	Comparison of the Return Rate between the two treatment arms.	Approximately 2 months